VESANOID

Phase 3Small molecule

UUniversity of Colorado, Denver

VESANOID is one of 97 small molecule programs targeting Head and Neck Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CarcinomaActive, not recruiting

LeukemiaActive, not recruiting

MelanomaActive, not recruiting

Head and Neck CarcinomaPhase 3

Active, not recruiting

LeukemiaPhase 3

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 2

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 3

Tuoyi

SSun Yat-sen University

Phase 3

4 4

Methylphenidate Hydrochloride

Takeda

Phase 3

1 5

ABP 234

Amgen

Phase 3

1 6

Isolated Perfusion

NNational Cancer Institute (NCI)

Phase 3

1 7

Tyrosinase Peptide

EEastern Cooperative Oncology Group

Phase 3

15 8

VESANOID

UUniversity of Colorado, Denver

Phase 3

1 9

Zelboraf

CConrado Roberto Hoffmann Filho

Intron a

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Head and Neck Carcinoma

NCT06706401

Clinical

Trials by Indication[1]

Head and Neck Carcinoma1 trial

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Recruiting·CCentre Leon Berard·Phase 3·NCT06706401·460 enrolled

Leukemia1 trial

ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)

Withdrawn·AAcute Leukemia French Association·Phase 3·NCT01067274

Melanoma1 trial

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Completed·UUniversity of Colorado, Denver·Phase 2·NCT02403778·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for VESANOID. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VESANOID compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VESANOID. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Colorado, Denver

VESANOID

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Head and Neck Carcinoma1 trial

Leukemia1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News